<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778634</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00054998</org_study_id>
    <secondary_id>R01HD067126</secondary_id>
    <nct_id>NCT01778634</nct_id>
  </id_info>
  <brief_title>Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants</brief_title>
  <acronym>AZIPIII</acronym>
  <official_title>A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercy Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christiana Care Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous azithromycin is effective in
      eradicating Ureaplasma respiratory tract infection in preterm infants born at 24 to 28 weeks
      gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design will be a double-blind, placebo-controlled clinical trial to test the
      efficacy and safety of azithromycin 20 mg/kg x 3 days to eradicate Ureaplasma spp from the
      respiratory tract of preterm infants 24 weeks 0 days to 28 weeks 6 days gestation exposed to
      positive pressure ventilation. The primary outcome will be survival with microbiological
      eradication of Ureaplasma defined as survival to discharge or transfer with 3 negative
      cultures obtained post-therapy. Secondary outcomes will include physiologic BPD at 36 weeks
      post-menstrual age (PMA), overall mortality, incidence of co-morbidities of prematurity such
      as intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis,
      bacterial and fungal nosocomial infection, pulmonary air leak, patent ductus arteriosus,
      retinopathy of prematurity, number of days of positive pressure ventilation, number of days
      of oxygen supplementation, use of postnatal steroids, and use of non-study antibiotics. At 6
      and 18 months adjusted age, a pulmonary outcome questionnaire will be administered by phone
      or in person interview. At 18-22 months adjusted age, neurodevelopmental outcomes will be
      assessed by 1) Bayley Scale of Infant and Toddler Development, 3rd edition (BSID-III); 2)
      Amiel-Tison neurologic examination; 3) Gross Motor Function Classification System; and 4)
      medical record review for hearing impairment with or without amplification and vision
      impairment (vision &lt;20/200).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Bacterial clearance (eradication) will be defined as 3 negative cultures obtained 2 and 5 days post-third dose and 21 d of age. Survival is defined as survival at time of discharge or transfer from the neonatal intensive care unit (NICU).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Survived Until 36 Wks Postmenstrual Age That Were Diagnosed With Physiologic Defined Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post Menstrual Age</measure>
    <time_frame>36 weeks post menstrual age (one month prior to due date)</time_frame>
    <description>Physiologic definition of BPD based on oxygen-saturation monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or Neurodevelopmental Impairment</measure>
    <time_frame>22-26 months</time_frame>
    <description>Neurodevelopmental impairment will be assigned if any of the following are present at 22-26 months adjusted age: moderate to severe cerebral palsy, bilateral blindness, bilateral hearing impairment requiring amplification, Gross Motor Function Classification System score ≥ 2, or Bayley Scale of Infant and Toddler Development, 3rd edition (BSID-III) cognitive or motor score &lt;70.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Impairment</measure>
    <time_frame>6-26 months</time_frame>
    <description>Parent report of recurrent wheezing and/or chronic cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died</measure>
    <time_frame>22-26 months</time_frame>
    <description>Mortality from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Positive Pressure Support</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Combined number of days receiving mechanical ventilation plus non-invasive modes of positive pressure support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Oxygen Supplementation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Receipt of supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Air Leaks</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Any pulmonary air leak (pulmonary interstitial emphysema, pneumothorax, pneumomediastinum) confirmed by chest x-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Postnatal Steroids</measure>
    <time_frame>36 weeks</time_frame>
    <description>Receipt of steroid medications (hydrocortisone, dexamethasone)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Non-Study Antibiotics</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Received Non-study antibiotics following study drug intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)/Pharmacodynamics (PD) Modelling of Time Course of Azithromycin Plasma Concentrations</measure>
    <time_frame>Study day 1-day 7</time_frame>
    <description>Number of serum azithromycin concentrations that fell within the 90% prediction interval determined by 200 simulated replicates based on the population PK of azithromycin in preterm infants.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Threshold Retinopathy of Prematurity (ROP)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Threshold ROP requiring surgical intervention as diagnosed by ophthalmologic examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Necrotizing Enterocolitis (NEC)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Necrotizing enterocolitis ≥ Bell Stage II by radiographic and clinical criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Infections During the NICU Hospitalization</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Culture-confirmed bacterial or fungal infection based on culture from sterile site (blood, cerebral spinal fluid, or urine)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Severe Intraventicular Hemorrhage (IVH)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>Grade III or IV IVH confirmed by cranial ultrasound</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Periventricular Leukomalacia (PVL)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
    <description>The number of subjects with cranial ultrasound confirmed PVL</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Patent Ductus Arteriosus (PDA)</measure>
    <time_frame>14 days</time_frame>
    <description>Detection of PDA by cardiac echocardiogram with left to right shunting, or clinical evidence of murmur, bounding pulses, and widened pulse pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Cardiac Arrhythmia</measure>
    <time_frame>3 days</time_frame>
    <description>EKG evidence of prolonged QT (QTc &gt; 450 ms)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Ureaplasma Infections</condition>
  <arm_group>
    <arm_group_label>Placebo (5% dextrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>D5W</description>
    <arm_group_label>Placebo (5% dextrose)</arm_group_label>
    <other_name>equal volume of 5% dextrose water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age 24 weeks 0 days-28weeks 6 days by best obstetrical estimate

          -  &lt;72 h age

          -  Positive pressure ventilation for at least 1 hour duration during the first 72 hours
             of life

          -  Presence of indwelling intravenous line for drug administration

        Exclusion Criteria:

          -  Any patient judged to be non-viable or for whom withdrawal of life support is planned

          -  Patients with major lethal congenital anomalies

          -  Triplets or higher order multiples

          -  Patients delivered for maternal indications (low risk of Ureaplasma colonization)

          -  Patients with EKG QT interval corrected for heart rate (Qtc) ≥ 450 ms

          -  Patients with significant hepatic impairment (direct bilirubin &gt;1.5 mg/dL)

          -  Patients exposed to other systemic macrolide

          -  Patients with clinically suspected Ureaplasma central nervous system (CNS) infection
             or other confirmed bacterial/viral infection

          -  Patients participating in other clinical trials involving investigational products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rose M Viscardi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pamela Donohue, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Namasivayam Ambalavanan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Kaufman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael L Terrin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan J Dulkerian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-9544</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0386</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hassan HE, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, Kaufman DA, Fairchild KD, Terrin ML, Viscardi RM. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. J Clin Pharmacol. 2011 Sep;51(9):1264-75. doi: 10.1177/0091270010382021. Epub 2010 Nov 23.</citation>
    <PMID>21098694</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <results_first_submitted>March 2, 2018</results_first_submitted>
  <results_first_submitted_qc>April 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2018</results_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Rose Viscardi</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Ureaplasma parvum</keyword>
  <keyword>Ureaplasma urealyticum</keyword>
  <keyword>prematurity</keyword>
  <keyword>bronchopulmonary dysplasia</keyword>
  <keyword>azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Ureaplasma Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period July 1, 2013- August 31, 2016 at 7 U.S. hospital Neonatal Intensive Care Units (NICUs).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (5% Dextrose)</title>
          <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
        </group>
        <group group_id="P2">
          <title>Azithromycin</title>
          <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (5% Dextrose)</title>
          <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
        </group>
        <group group_id="B2">
          <title>Azithromycin</title>
          <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>gestational age in weeks</description>
          <units>weeks gestation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="1.4"/>
                    <measurement group_id="B2" value="26.2" spread="1.4"/>
                    <measurement group_id="B3" value="26.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ureaplasma-positive</title>
          <description>Any subject who had a respiratory sample (tracheal aspirate and/or nasopharyngeal aspirate) at any time point that was positive for Ureaplasma species confirmed by culture and/or PCR was considered a Ureaplasma-positive subject.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma</title>
        <description>Bacterial clearance (eradication) will be defined as 3 negative cultures obtained 2 and 5 days post-third dose and 21 d of age. Survival is defined as survival at time of discharge or transfer from the neonatal intensive care unit (NICU).</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma</title>
          <description>Bacterial clearance (eradication) will be defined as 3 negative cultures obtained 2 and 5 days post-third dose and 21 d of age. Survival is defined as survival at time of discharge or transfer from the neonatal intensive care unit (NICU).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.53</ci_lower_limit>
            <ci_upper_limit>22.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Survived Until 36 Wks Postmenstrual Age That Were Diagnosed With Physiologic Defined Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post Menstrual Age</title>
        <description>Physiologic definition of BPD based on oxygen-saturation monitoring</description>
        <time_frame>36 weeks post menstrual age (one month prior to due date)</time_frame>
        <population>Participants who survived until assessment timepoint 36 weeks post menstrual age (1 month before due date)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Survived Until 36 Wks Postmenstrual Age That Were Diagnosed With Physiologic Defined Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post Menstrual Age</title>
          <description>Physiologic definition of BPD based on oxygen-saturation monitoring</description>
          <population>Participants who survived until assessment timepoint 36 weeks post menstrual age (1 month before due date)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death or Neurodevelopmental Impairment</title>
        <description>Neurodevelopmental impairment will be assigned if any of the following are present at 22-26 months adjusted age: moderate to severe cerebral palsy, bilateral blindness, bilateral hearing impairment requiring amplification, Gross Motor Function Classification System score ≥ 2, or Bayley Scale of Infant and Toddler Development, 3rd edition (BSID-III) cognitive or motor score &lt;70.</description>
        <time_frame>22-26 months</time_frame>
        <posting_date>01/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Impairment</title>
        <description>Parent report of recurrent wheezing and/or chronic cough</description>
        <time_frame>6-26 months</time_frame>
        <posting_date>01/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died</title>
        <description>Mortality from any cause</description>
        <time_frame>22-26 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died</title>
          <description>Mortality from any cause</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Positive Pressure Support</title>
        <description>Combined number of days receiving mechanical ventilation plus non-invasive modes of positive pressure support.</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Positive Pressure Support</title>
          <description>Combined number of days receiving mechanical ventilation plus non-invasive modes of positive pressure support.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="17" upper_limit="60"/>
                    <measurement group_id="O2" value="39" lower_limit="19" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>To include non-survivors as bad values of this outcome we imputed a high value for the participants who died. Note, because we analyzed the data using a nonparametric test, the actual value doesn't affect the analysis, only the rank of the value.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Oxygen Supplementation</title>
        <description>Receipt of supplemental oxygen</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Oxygen Supplementation</title>
          <description>Receipt of supplemental oxygen</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="33" upper_limit="95"/>
                    <measurement group_id="O2" value="68" lower_limit="32" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>To include non-survivors as bad values of this outcome we imputed a high value for the participants who died. Note, because we analyzed the data using a nonparametric test, the actual value doesn't affect the analysis, only the rank of the value.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Air Leaks</title>
        <description>Any pulmonary air leak (pulmonary interstitial emphysema, pneumothorax, pneumomediastinum) confirmed by chest x-ray</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <population>The participants who had air leak at baseline (prior to randomization) were excluded from analysis (3 placebo and 5 azithromycin).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Air Leaks</title>
          <description>Any pulmonary air leak (pulmonary interstitial emphysema, pneumothorax, pneumomediastinum) confirmed by chest x-ray</description>
          <population>The participants who had air leak at baseline (prior to randomization) were excluded from analysis (3 placebo and 5 azithromycin).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Postnatal Steroids</title>
        <description>Receipt of steroid medications (hydrocortisone, dexamethasone)</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Postnatal Steroids</title>
          <description>Receipt of steroid medications (hydrocortisone, dexamethasone)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Non-Study Antibiotics</title>
        <description>Received Non-study antibiotics following study drug intervention period.</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Non-Study Antibiotics</title>
          <description>Received Non-study antibiotics following study drug intervention period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK)/Pharmacodynamics (PD) Modelling of Time Course of Azithromycin Plasma Concentrations</title>
        <description>Number of serum azithromycin concentrations that fell within the 90% prediction interval determined by 200 simulated replicates based on the population PK of azithromycin in preterm infants.</description>
        <time_frame>Study day 1-day 7</time_frame>
        <population>No plasma samples from placebo group were analyzed for azithromycin concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK)/Pharmacodynamics (PD) Modelling of Time Course of Azithromycin Plasma Concentrations</title>
          <description>Number of serum azithromycin concentrations that fell within the 90% prediction interval determined by 200 simulated replicates based on the population PK of azithromycin in preterm infants.</description>
          <population>No plasma samples from placebo group were analyzed for azithromycin concentrations</population>
          <units>serum concentrations</units>
          <param>Number</param>
          <units_analyzed>number of serum samples concentrations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of serum samples concentrations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Threshold Retinopathy of Prematurity (ROP)</title>
        <description>Threshold ROP requiring surgical intervention as diagnosed by ophthalmologic examination</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <population>The number of participants who survived to receive at least 1 eye exam for retinopathy of prematurity</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Threshold Retinopathy of Prematurity (ROP)</title>
          <description>Threshold ROP requiring surgical intervention as diagnosed by ophthalmologic examination</description>
          <population>The number of participants who survived to receive at least 1 eye exam for retinopathy of prematurity</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Necrotizing Enterocolitis (NEC)</title>
        <description>Necrotizing enterocolitis ≥ Bell Stage II by radiographic and clinical criteria.</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Necrotizing Enterocolitis (NEC)</title>
          <description>Necrotizing enterocolitis ≥ Bell Stage II by radiographic and clinical criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Infections During the NICU Hospitalization</title>
        <description>Culture-confirmed bacterial or fungal infection based on culture from sterile site (blood, cerebral spinal fluid, or urine)</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infections During the NICU Hospitalization</title>
          <description>Culture-confirmed bacterial or fungal infection based on culture from sterile site (blood, cerebral spinal fluid, or urine)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Severe Intraventicular Hemorrhage (IVH)</title>
        <description>Grade III or IV IVH confirmed by cranial ultrasound</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <population>The participants who had a Grade III or IV IVH at baseline (prior to randomization) were excluded (2 placebo and 4 Azithromycin).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Intraventicular Hemorrhage (IVH)</title>
          <description>Grade III or IV IVH confirmed by cranial ultrasound</description>
          <population>The participants who had a Grade III or IV IVH at baseline (prior to randomization) were excluded (2 placebo and 4 Azithromycin).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Periventricular Leukomalacia (PVL)</title>
        <description>The number of subjects with cranial ultrasound confirmed PVL</description>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Periventricular Leukomalacia (PVL)</title>
          <description>The number of subjects with cranial ultrasound confirmed PVL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Patent Ductus Arteriosus (PDA)</title>
        <description>Detection of PDA by cardiac echocardiogram with left to right shunting, or clinical evidence of murmur, bounding pulses, and widened pulse pressure.</description>
        <time_frame>14 days</time_frame>
        <population>Participants who did not have PDA at baseline (prior to randomization). Participants with PDA at baseline were excluded from analysis (5 placebo and 5 azithromycin.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Patent Ductus Arteriosus (PDA)</title>
          <description>Detection of PDA by cardiac echocardiogram with left to right shunting, or clinical evidence of murmur, bounding pulses, and widened pulse pressure.</description>
          <population>Participants who did not have PDA at baseline (prior to randomization). Participants with PDA at baseline were excluded from analysis (5 placebo and 5 azithromycin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Cardiac Arrhythmia</title>
        <description>EKG evidence of prolonged QT (QTc &gt; 450 ms)</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (5% Dextrose)</title>
            <description>Placebo
Placebo: D5W</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Arrhythmia</title>
          <description>EKG evidence of prolonged QT (QTc &gt; 450 ms)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (5% Dextrose)</title>
          <description>Placebo
Placebo: D5W 10 ml/kg every 24 h x 3 days</description>
        </group>
        <group group_id="E2">
          <title>Azithromycin</title>
          <description>Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>hematocrit &lt;25</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>White blood cell count &gt;40,000 cells/mm3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>platelet count &lt;50,000</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Patent Ductus Arteriosus</sub_title>
                <description>Patent ductus arteriosus confirmed by cardiac echocardiography</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy of prematurity</sub_title>
                <description>Retinopathy of prematurity (ROP) &gt;Stage 2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Necrotizing enterocolitis</sub_title>
                <description>Necrotizing enterocolitis Bell Stage ≥2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ileal stricture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Positive culture from a sterile site (blood or spinal fluid)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Urea Nitrogen &gt; 60 mg/dL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>Serum calcium level &gt;12.2 mg/dL</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypochloremia</sub_title>
                <description>Serum chloride &lt;80 mEq/L</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>Serum sodium &gt;155 mEq/L</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Serum potassium &lt;2.4 mEq/L</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Serum sodium &lt;121 mEq/L</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <description>Breathing pause &gt; 20 seconds</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>white blood cell count &gt;20,000 and &lt;40,000 cells/mm3</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>platelet count &lt;100,000 and &gt;50,000 cells/mm3</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>hematocrit &lt;35% and &gt;25%</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastric residual &gt;50% volume of feed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <description>Abdominal girth increase &gt; 2cm from baseline</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <description>stool consistency change with more water content &lt;48 h duration</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver function test</sub_title>
                <description>Serum liver function test (AST/ALT/ or alkaline phosphatase) 1.5-3.5X normal value</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>conjugated hyperbilirubinemia</sub_title>
                <description>Direct bilirubin 1.0-2.0 mg/dL</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <description>Total bilirubin &gt; 7 and &lt;14 mg/dL</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral thrush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolic acidosis</sub_title>
                <description>Serum bicarbonate &lt;22 and &gt;14 mEq/L</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <description>Serum bicarbonate &gt;30 and &lt;46 mEq/L</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Elevated Blood Urea Nitrogen</sub_title>
                <description>Serum BUN &gt;27 and &lt;60 mg/dL</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Serum potassium &gt;5.5 and &lt;6.9 mEq/L</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>Serum sodium &lt;132 and &gt;120 mEq/dL</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated serum creatinine</sub_title>
                <description>Serum creatinine 1.3-2.3 mg/dL</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>IV site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rose Marie Viscardi, M.D.</name_or_title>
      <organization>University of Maryland</organization>
      <phone>410-706-1913</phone>
      <email>rviscard@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

